Recommendation No. 56/2024 of 14 June 2024 of the President of the Agency for Health Technology Assessment and Tariff System on the evaluation of the drug Akeega (niraparyb + abiraterone acetate) as part of the drug program: B.56. “Treatment of patients with cancer of the Prostate (ICD-10: C61)”.